Yahoo won't allow me to post the website, but you can find it easily enough. Head & neck and colon cancer indications to follow. Cardinal to launch lymphoseek soon. EU partnership soon. Alzheimer's and Parkinson's drugs to start Phase 3 trials later this year.
The FDA announced their marketing app roval for Navidea s Lymphoseek (technetium Tc 99m tilmanocept)
Injection, in patients with breast cancer or melanoma who are undergoing surgery to remove tumor
- draining lymph nodes.
The FDA stated: Lymphoseek is the first new drug used for lymph node mapping to be approved in more
than 30 years. We also note the FDA approval came 6 weeks early from the April 30 th PDUFA date.
We expect (NYSE: CAH) to now execute a timely U.S. launch with their significant sales force (currently generating sales over $100 billion) as well as leveraging their existing nuclear pharm acies and cyclotron facilities. Gross margins exprected to be 75% to 80% which translates to 35% - 40% of CAH's sales
revenue from Lymphoseek.......